Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 12, 2005, Pages 1765-1768

  Askling, Johan ^a   Klareskog, L ^a   Hjalgrim, H ^b   Baecklund, E ^c   Bjorkholm M ^a   Ekbom, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GIANT CELL ARTERITIS; HODGKIN DISEASE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGISTER; RHEUMATIC POLYMYALGIA; RISK ASSESSMENT; SWEDEN;

AGED; ANTIRHEUMATIC AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HODGKIN DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; SWEDEN; TEMPORAL ARTERITIS;

EID: 27944454280     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.036459     Document Type: Article

References (36)

1. Cartwright RA, McKinney PA, O'Brien C, Richards ID, Roberts B, Louder I, et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res 1988;12:81-8.
2. Bernstein L, Ross RK. Prior medication use and health history as risk factors tor non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992;52:5510-15s.
3. Zhang Y, Holfprd TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior Medical Conditions and Medication use and Risk of non-Hodgkin lymphoma in Connecticut United States Women. Cancer Causes Control 2004;15:419-28.
4. Kato I, Koenig KL, Shore RE, Baptiste MS, Lillquist PP, Frizzera G, et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 2002;13:965-74.
5. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 2003;158:316-27.
6. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003;14:639-44.
7. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-11.
8. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-70.
9. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71.
10. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer, 1995;60:183-9.
11. Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996;20:1279-87.
12. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
13. Kinlen U. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
14. Hazleman BL. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982;41(suppl 1):12-17.
15. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
16. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.
17. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42:374-8.
18. Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 2003;21(6 suppl 32):S29-34.
19. Patientregistret 1987-1996 Kvalitet och innehall. Stockholm: Epidemiologiskt Centrum, Socialstyrelsen, 1998.
20. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-13.
21. World Health Organisation International classification of diseases. Geneva: WHO, 1955.
22. Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2, 1980;2:1-59.
23. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 2002;29:2143-7.
24. Haga HJ, Eide GE, Brun J, Johansen A, Langmark F. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1993;20:1335-9.
25. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995;34:261-4.
26. Salvarani C, Macchioni PL, Tartoni PL, Rossi F, Baricchi R, Castri C, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987;5:205-15.
27. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996;100:193-6.
28. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
29. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis. Arthritis & Rheumatism 1998;41(suppl 9):188.
30. Baecklund E, Ekbom A, Feltelius N, Iliadou A, Backlin C, Askling J, et al. Disease activity, but not DMARD use, increases the risk for malignant lymphoma in rheumatoid arthritis: a case-control study of 378 RA lymphoma patients. Ann Rneum Dis 2004;63(suppl 1):103.
31. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Association of aspirin and other non-steroidal antiinflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 2003;106:784-8.
32. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with WegeneKs granulomatosis. Int J Cancer 2002;100:82-5.
33. Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002;29:906-12.
34. Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999;38:1208-12.
35. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann intern Med 1995;123:192-4.
36. Duhaut P, Bosshard S, Dumontet C. Giant cell arteritis and polymyalgia rheumatica: role of viral infections. Clin Exp Rheumatol 2000;18(4 suppl 20):S22-3.